ICAIR

As a close-knit research alliance, iCAIR® is working on the development of anti-infective therapies that take new treatment options all the way from the identification of potentially beneficial substances to the preclinical proof of concept. In selected lighthouse projects, iCAIR® is establishing and demonstrating its position as an expert preclinical development platform for new anti-infective drugs. One objective of these projects is to target new treatments to combat the pathogens Pseudomonas aeruginosa, Aspergillus fumigatus, Neisseria meningitidis, different respiratory viruses such as the human parainfluenza and influenza viruses, RSV, and coronaviruses, and develop these treatments to the point of preclinical proof of concept.

Primary location: Hannover